Charles Schwab Investment Management Inc Moleculin Biotech, Inc. Transaction History

Charles Schwab Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.85 - $16.65 $31,115 - $609,489	36,606 New	36,606 $38,000
Q2 2022 Aug 15, 2022	BUY	$1.19 - $2.0 $13,394 - $22,512	11,256 Added 55.73%	31,454 $46,000
Q3 2021 Nov 16, 2021	BUY	$2.7 - $3.59 $54,534 - $72,510	20,198 New	20,198 $61,000
Q2 2021 Aug 16, 2021	SELL	$3.21 - $4.06 $39,056 - $49,398	-12,167 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$3.7 - $6.42 $45,017 - $78,112	12,167 New	12,167 $50,000

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $73.2M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.